相关实验视频

Updated: Jun 3, 2025

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

第三代与第一代EGFR-TKI在EGFR突变局部晚期或转移性非小细胞肺癌的第一线治疗中:基于随机对照试验的元分析

Wenjie Hu¹, Yi Qin¹, Taoming Dong¹

¹Department of Oncology, The Second People's Hospital of Jingdezhen, Jingdezhen, China.

Journal of Cancer

|January 9, 2025

概括

与第一代EGFR-TKIs (FGET) 相比,第三代EGFR-TKIs (TGET) 在晚期EGFR突变NSCLC中显示出更好的生存率和反应. 然而,TGET与较高的严重不良事件发生率有关,需要谨慎的患者管理.

科学领域:

在瘤学瘤学.
药理学药理学是指药理学的学科.
临床医学临床医学

背景情况:

普遍认为,第三代EGFR-TKIs (TGET) 优于第一代EGFR-TKIs (FGET) 对于先进的EGFR突变NSCLC.
这种信念缺乏强有力的基于证据的证据.
进行了一项元分析,严格比较TGET与FGET的疗效和安全性.

研究的目的:

将第三代EGFR-TKI (TGET) 与第一代EGFR-TKI (FGET) 的疗效和不良影响进行比较.
评估终点,包括无进展生存率 (PFS),总生存率 (OS) 和中枢神经系统PFS (CNS-PFS).
评估与两代TKI相关的治疗反应和不良事件.

主要方法:

在七个数据库中系统地搜索相关的随机对照试验 (RCT) 的文献.
分析了来自6个RCT的15项研究,涉及6个第三代TKI (奥西默蒂尼布,拉泽蒂尼布,弗蒙尔蒂尼布,奥莫尔蒂尼布,纳科蒂尼布,贝福特蒂尼布).
主要终点包括PFS,OS,中枢神经系统-PFS,客观反应率 (ORR) 和不良事件.

主要成果:

与FGET相比,TGET在PFS (HR:0.55),中枢神经系统-PFS (HR:0.48),中枢神经系统-ORR (RR:1.40) 和DOR (HR:0.52) 中表现出更高的疗效.
虽然OS,ORR和AEs总量相似,但TGET显示严重不良事件的发生率更高 (RR: 1.17).
特定的3-4级AE在TGET中更为频繁,包括腹,皮疹和血小板数量下降,但在ALT/AST升高时不太频繁.

结论:

第三代EGFR-TKIs (TGET),不包括Naquotinib,在晚期EGFR突变NSCLC中优于FGET,改善了生存率和反应率.
由于TGET严重不良事件的发生率增加,因此需要仔细监测和管理策略.
进一步的研究可能会探索优化TGET的使用,以减轻不良影响,同时最大限度地提高治疗效益.

关键词:

第一个世代的第一代.进行元分析分析.非小细胞肺癌是非小细胞肺癌.第三代的第三代人.铁氨酸激酶抑制剂铁氨酸激酶抑制剂

更多相关视频

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds

Published on: April 6, 2016

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Mitogens and the Cell Cycle

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...